Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.

[1]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[2]  C. Dinardo.  Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia. , 2018, The New England journal of medicine.

[3]  J. Loscalzo,et al.  Quantification of 2-Hydroxyglutarate Enantiomers by Liquid Chromatography-mass Spectrometry. , 2016, Bio-protocol.

[4]  K. Nair,et al.  Impact of Long-Term Poor and Good Glycemic Control on Metabolomics Alterations in Type 1 Diabetic People. , 2016, The Journal of clinical endocrinology and metabolism.

[5]  A. Tefferi,et al.  Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia , 2015, Blood Cancer Journal.

[6]  B. Ko,et al.  The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia , 2011, Leukemia.

[7]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[8]  Michael Heuser,et al.  IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis , 2010, Haematologica.

[9]  W. van Putten,et al.  Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. , 2010, Blood.

[10]  H. Dombret,et al.  Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Hai Yan,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.

[13]  D. Gilliland,et al.  IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis , 2010, Leukemia.

[14]  A. Tefferi,et al.  Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q) , 2010, Leukemia.

[15]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Birnbaum,et al.  Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.

[17]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[18]  T. Hankemeier,et al.  Microbial metabolomics with gas chromatography/mass spectrometry. , 2006, Analytical chemistry.

[19]  N. Verhoeven,et al.  Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. , 2004, Clinical chemistry.

[20]  A. Zamyatnin,et al.  Protein volume in solution. , 1972, Progress in biophysics and molecular biology.